Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age11-19
SponsorUniversity Hospital, Motol

About this trial

The proposed project is a clinical intervention trial testing the feasibility and effectiveness of diabetic retinopathy screening evaluated by artificial intelligence (AI) based software in children with type 1 diabetes (CwD). Another novel method, the confocal microscopy of the retina will be used to assess the early stages of diabetic neuropathy. In parallel, we aim to assess the prevalence of diabetic retinopathy and neuropathy in a well-controlled population of CwD at a tertiary diabetes care center.

Each participant will undergo an examination of diabetic retinopathy using the non-mydriatic fundus camera. The resulting photography will be evaluated by AI driven software. The participant will then follow this examinaton with fundus ophtalmoscopy in arteficial mydriasis as a standard method of diabetic retinopathy assessment. Another method, the optic coherence tomography (OCT), which is considered as the most sensitive method for diabetic retinopathy assessment, will be performed after that. The results of these methods will be compared to assess the sensitivity of each. The examination-satisfaction questionnaire will be given to the participants.

In subjects over 18 years, a confocal microscopy of the retina examination will be performed to assess the status of the corneal sub-basal nerve plexus and the presence of diabetic neuropathy will be noted.

The prevalence of diabetic retinopathy and neuropathy in this group of children with diabetes will be assessed based on the results.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Type 1 diabetes diagnosed according to the ADA criteria

Age over 11.0 years or duration of diabetes over 2 years

Signed written informed consent by both the CwD and their parent/caregiver

Disqualifiers

Unwillingness to sign a written informed consent by both the CwD and their parent/caregiver

Trial design

Design model

Single group

Treatments tested in this trial

  • Non-mydriatic fundus camera photography

    Diagnostic test

    Non-mydriatic fundus camera photography assessed by artificial intelligence software

  • Fundus ophtalmoscopy

    Diagnostic test

    Fundus opthalmoscopy assessed by an experienced ophtalmologist

  • Optic coherence tomography

    Diagnostic test

    Optic coherence tomography assessed by an experienced ophtalmologist

  • Confocal microscopy of the retina

    Diagnostic test

    In a subset of participants over 18 years of age, confocal microscopy of the retina will be performed to assess the presence of diabetic neuropathy

Treatment groups

400 Participants
are divided into 1 treatment group
Group A: Study armExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Feasibility of AI for retinopathy screening

The primary objective of this study is to test whether performing the diabetic retinopathy screening using the non-mydriatic fundus camera with AI software is feasible. The exact outcome is the percent of participants who will agree to undergo the procedure and will obtain a valid result (either positive or negative).

Time frame
Through study completion, on average 6 months.

Secondary outcomes

1

Examination satisfaction

Participant and caregiver reported examination satisfaction assessed by a structured questionnaire on a Lickert scale from 1 to 5.

Time frame
Through study completion, on average 6 months.
2

Prevalence of diabetic retinopathy

Prevalence of diabetic retinopathy among CwD in a single center with favorable glucose control

Time frame
Through study completion, on average 6 months.
3

Prevalence of diabetic neuropathy

Prevalence of diabetic neuropathy in young people with diabetes (over 18 years) in a single center with favorable glucose control

Time frame
Through study completion, on average 6 months.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.